文献速递放疗物理与技术姑息放疗与转移瘤

区域放疗网络无症状患者系统性SARS-CoV-2检测的实施、依从性与结果

Implementation, adherence, and results of systematic SARS-CoV-2 testing for asymptomatic patients treated at a tertiary care regional radiation oncology network.
PubMed 文献 · Radiat Oncol · 2021-02-04

该研究在美国夏洛特地区大型放疗网络对接受放疗的无症状患者实施系统性SARS-CoV-2 PCR检测,共纳入604例患者,放疗前检测依从率94.9%(573例),阳性4例(0.7%);放疗期间检测总体依从率91.6%,新增阳性4例(0.7%),累计阳性8例(1.3%),未发现感染者向工作人员或其他患者的传播。

要点

  • 放疗前PCR检测依从率94.9%,阳性率0.7%。
  • 放疗期间检测总体依从率91.6%,新增阳性4例(0.7%)。
  • 累计8例(1.3%)阳性,未发现感染者向工作人员或其他患者传播。

核心结论

  • 在大型放疗网络对无症状患者实施系统性SARS-CoV-2 PCR检测,放疗前与放疗期间依从率均较高,累计阳性率1.3%,未发现感染者向工作人员或其他患者传播。

研究设计与样本

  • 前瞻性实施性队列研究,纳入2020年5月18日至7月10日在Levine Cancer Institute放疗网络接受放疗模拟定位的患者,共604例。
  • 纳入标准为无COVID-19相关症状、既往无SARS-CoV-2阳性检测、无近期高危接触史。
  • PCR检测采用鼻腔或鼻咽拭子样本,放疗开始前2周内检测(pre-RT),长疗程放疗患者放疗期间至少每4周检测一次(intra-RT)。
  • 利用肿瘤电子病历(EMR)开发了基于任务的自动化流程用于检测管理。

主要发现

  • 放疗前PCR检测在573例(94.9%)患者中完成,其中4例(0.7%)阳性。
  • 放疗期间检测总体依从率为91.6%。
  • 放疗期间新增4例(0.7%)阳性,其中3例因出现症状而检测,1例无症状者经系统性检测发现。
  • 累计8例(1.3%)患者检测阳性。
  • 未发现SARS-CoV-2从感染患者传播至诊所工作人员和/或其他患者的已知病例。

关键数值与推荐

  • 放疗前检测依从率94.9%(573/604),阳性4例(0.7%)。
  • 放疗期间检测总体依从率91.6%,新增阳性4例(0.7%)。
  • 累计阳性8例(1.3%)。
  • 放疗期间检测频率为至少每4周一次(针对长疗程放疗患者)。

临床怎么用

  • 该流程使RT启动得以适当延迟,最大限度减少RT治疗中断。
  • 系统性检测有助于识别无症状感染者,避免其向工作人员和其他患者传播。
  • 基于EMR的自动化任务流程可用于支持系统性检测的实施与依从性管理。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus is a current pandemic. We initiated a program of systematic SARS-CoV-2 polymerase chain reaction (PCR) testing in all asymptomatic patients receiving radiotherapy (RT) at a large radiation oncology network in the Charlotte, NC metropolitan region and report adherence and results of the testing program. METHODS: Patients undergoing simulation for RT between May 18, 2020 and July 10, 2020 within the Levine Cancer Institute radiation oncology network who were asymptomatic for COVID-19 associated symptoms, without previous positive SARS-CoV-2 testing, and without recent high-risk contacts were included. PCR testing was performed on nasal cavity or nasopharyngeal swab samples. Testing was performed within 2 weeks of RT start (pre-RT) and at least every 4 weeks during RT for patients with prolonged RT courses (intra-RT). An automated task based process using the oncology electronic medical record (EMR) was developed specifically for this purpose. RESULTS: A total of 604 unique patients were included in the cohort. Details on testing workflow and implementation are described herein. Pre-RT PCR testing was performed in 573 (94.9%) patients, of which 4 (0.7%) were positive. The adherence rate to intra-RT testing overall was 91.6%. Four additional patients (0.7%) tested positive during their RT course, of whom 3 were tested due to symptom development and 1 was asymptomatic and identified via systematic testing. A total of 8 (1.3%) patients tested positive overall. There were no known cases of SARS-CoV-2 transmission from infected patients to clinic staff and/or other patients. CONCLUSIONS: We detailed the workflows used to implement systematic SARS-CoV-2 for asymptomatic patients at a large radiation oncology network. Adherence rates for pre-RT and intra-RT testing were high using this process. This information allowed for appropriate delay in initiating RT, minimizing the occurrence of RT treatment interruptions, and no known cases of transmission from infected patients to clinic staff and/or other patients.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Prabhu RS, Dhakal R, Hicks AS, et al. Implementation, adherence, and results of systematic SARS-CoV-2 testing for asymptomatic patients treated at a tertiary care regional radiation oncology network. Radiat Oncol. 2021. PMID: 33541359. doi:10.1186/s13014-021-01760-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。